Complete Conference Management 30th Annual Heart Failure 2026: An Update on Therapy

Complete Conference Management 30th Annual Heart Failure 2026: An Update on Therapy

Get on-demand digital access to the 30th Annual Heart Failure 2026: An Update on Therapy, a comprehensive cardiovascular education program focused on the prevention, diagnosis, and management of acute and chronic heart failure.

This program provides a highly specialized review of advanced heart failure management, covering the latest clinical updates in pharmacotherapy, guideline-directed medical therapy, device therapy, genetic testing, cardiomyopathies, myocarditis, cardiogenic shock, pulmonary hypertension, amyloidosis, and complex patient care scenarios.

Recorded during the live hybrid symposium held on March 13–14, 2026, this educational program features expert-led lectures, case discussions, and clinically relevant updates designed to help healthcare professionals improve the care of patients with heart failure across diverse etiologies.

Included:

• Conference video recordings
• Subtitle files: VTT
• PDF learning materials
• Total size: GB
• Format: Digital access
• Sample video: Available upon request

Target Audience:
This program is ideal for cardiologists, internists, primary care physicians, advanced heart failure specialists, intensivists, pharmacists, nurses, and other healthcare professionals involved in the care of patients with heart failure.

Learning Objectives:
At the conclusion of this activity, participants should be able to:

• Review current updates in the management of cardiovascular conditions, including hypertension, hyperlipidemia, heart failure with reduced ejection fraction, and heart failure with preserved ejection fraction.
• Discuss advanced treatment strategies for acute decompensated heart failure, heart failure with kidney disease, atrial fibrillation in heart failure patients, cardiogenic shock, and valvular heart disease interventions.
• Explore specialized management approaches for hypertrophic cardiomyopathy, amyloidosis, obesity in heart failure, pulmonary arterial hypertension, myocarditis, and peripartum cardiomyopathy.
• Understand innovations in device therapy, AI-assisted heart failure management, autonomic modulation, LVAD therapy, heart transplantation, and emerging genetic and cellular therapies.

Main Topics Covered:

• Management of hospitalized patients with decompensated heart failure
• Balancing GDMT and hyperkalemia
• Digitoxin and digitalis therapy in heart failure
• Finerenone in heart failure and chronic kidney disease
• Vericiguat in heart failure
• Contemporary management of HFpEF
• Diuretic therapy and congestion management
• Myocarditis and cancer therapy-related cardiac complications
• Myosin inhibitors for hypertrophic cardiomyopathy
• Obesity management in heart failure patients
• GDMT optimization for chronic HFrEF
• Cardiogenic shock classification and management
• Percutaneous coronary interventions in ischemic cardiomyopathy
• Bio-omics in heart failure diagnosis and therapy
• Genetic testing for cardiomyopathy
• Gene therapy and stem cell therapy in myocardial disease
• Methamphetamine-associated cardiomyopathy
• Atrial fibrillation in heart failure patients
• Peripartum cardiomyopathy
• ESC 2025 myocarditis guideline updates
• Pulmonary hypertension therapies
• Innovations in device therapy for heart failure
• AI in heart failure management
• Autonomic modulation in heart failure treatment
• LVAD vs heart transplantation
• Drug therapy selection in transthyretin amyloidosis

Program Sessions:

• Case Discussions
• Product Theatre Breakfast – Non-CME Navigating Fabry Disease
• Session I
• Session II
• Session III
• Session IV
• Session V
• Session VI

Detailed Program Agenda

Friday, March 13, 2026

Session I

• Introduction to the 30th Annual Symposium: Heart Failure 2026 – An Update on Therapy
• Management of the Hospitalized Patients with Decompensated Heart Failure
• Balancing GDMT and Hyperkalemia
• Digitoxin in Heart Failure: A Comeback for Digitalis?
• Introducing Finerenone: A New Drug for the Management of Heart Failure and Chronic Kidney Disease
• Vericiguat in Heart Failure: When and How to Use It
• The Contemporary Management of HFpEF

Session II

• Our Journey with Diuretics: 240 Years, and How Far Have We Come?
• Treating Congestion in Patients with Acute Decompensated Heart Failure: Where Are We Now? Where Are We Going?
• Releasing the Brakes on the Immune System in Cancer: Implications in Myocarditis and Beyond
• Clinical Experience with the Use of Myosin Inhibitors in the Treatment of Obstructive and Non-Obstructive Hypertrophic Cardiomyopathy
• Contemporary Management of Obesity in Patients with Heart Failure

Saturday, March 14, 2026

Case Discussion

• Heart failure case discussion with expert faculty

Session III

• Introduction to Day Two: 30th Annual Symposium: Heart Failure 2026 – An Update on Therapy
• GDMT for Chronic HFrEF: How to Maximize the Benefits?
• Cardiogenic Shock: Hemodynamic Classification and Management
• Percutaneous Coronary Interventions in Ischemic Cardiomyopathy – Does It Work?
• Bio-Omics in Heart Failure Diagnosis and Therapy

Session IV

• Genetic Testing for Cardiomyopathy
• Gene Therapy for Patients with Cardiomyopathy
• Stem Cell Therapy for the Management of Myocardial Disease: A Status Report
• Clinical Characteristics and Management of Methamphetamine-Associated Cardiomyopathy
• Update on the Management of Atrial Fibrillation in Patients with Heart Failure

Session V

• Keynote Lecture: 30 Years of Innovation in the Management of Heart Failure – A Perspective
• Bromocriptine in the Management of Peripartum Cardiomyopathy: Pathophysiologic Mechanism and Available Data
• What Is New in Myocarditis: An Update from the ESC 2025 Guidelines
• Pulmonary Hypertension: New Drugs and How to Use Them
• Innovations in Device Therapy for Heart Failure

Session VI

• The Use of AI in the Management of Heart Failure
• Autonomic Modulation in Heart Failure Treatment: Where Are We and Where Are We Heading?
• LVAD vs Heart Transplantation: A Perspective
• Individual Selection of Drug Therapy in Patients with Transthyretin (TTR) Amyloidosis

Access the full Heart Failure 2026 digital course and review expert-led cardiovascular updates anytime, anywhere.